• Home

Drug Crisis: What is the Arkansas State Doing to Control the Epidemic?

Pre-Conditions for the Growth of Addiction

The United States faces a severe drug addiction crisis, with overdose deaths peaking in recent years due to synthetic opioids like fentanyl, which were involved in 69% of all overdose deaths in 2023. Opioid addiction remains dominant, though marijuana use has increased alongside it, contributing to broader substance misuse patterns. In Arkansas specifically, opioid prescriptions averaged over 70 per 100 people in 2023, nearly twice the national rate, fueling ongoing addiction issues.

The crisis originated from overprescription of opioids in the late 1990s and early 2000s, leading to widespread dependency as patients transitioned to illicit alternatives like heroin and fentanyl. The influx of synthetic opioids into the illicit drug supply spiked deaths starting in 2020, coinciding with COVID-19 disruptions in healthcare, increased isolation, and mental health stressors. Economic factors, such as unemployment, have correlated with higher misuse rates, with 4.1% of unemployed adults misusing opioids in 2023. Aggressive marketing by pharmaceutical companies and inadequate regulation exacerbated the spread, while post-pandemic surges saw opioid use disorder diagnoses in Arkansas reach 1,218 per 100,000 commercially insured individuals in 2024, more than twice the national average.

Social and Economic Impacts

Opioid and general drug addiction have overwhelmed U.S. healthcare systems, with Arkansas alone seeing opioid use disorder diagnoses cost an average of $551,000 per case annually, straining insurers and providers. Public safety is compromised by rising non-fatal overdoses and related crimes; in Arkansas, programs like ARORP responded to 206 non-fatal overdoses and made 385 arrests in the past year, indicating persistent enforcement needs. Productivity suffers as addiction affects working-age groups, with 35.2% of Arkansas diagnoses in the 31-40 age range and 28% in 41-50, leading to workforce losses and higher unemployment-linked misuse at 4.1% nationally. Marijuana addiction, while less lethal, compounds mental health burdens and emergency visits.

Broader economic fallout includes massive healthcare expenditures and reduced output, with national overdose deaths involving synthetic opioids driving up costs. In Arkansas, despite a 24% drop in total overdoses to 391 in 2024, opioids factored in 60.9% of 2023 overdose deaths (314 total), with fentanyl in 85.4%, underscoring ongoing public safety risks like daily fatalities—one person dies every day. Socially, families face devastation, with programs referring 883 people to treatment amid stable arrest rates, highlighting intergenerational impacts and the need for sustained intervention.

Federal Countermeasures

• Over-the-Counter Naloxone Approval (March 2023)
  

  The U.S. Food and Drug Administration (FDA) approved over-the-counter sales of naloxone, a lifesaving opioid overdose reversal drug, making it widely accessible without a prescription. This targets the general public, first responders, and high-risk individuals to reverse fentanyl-driven overdoses, which caused most U.S. deaths in 2023. It contributes by increasing availability nationwide, mirroring Arkansas's 365% naloxone prescription jump post-state mandate. Early data shows potential in reducing fatalities, as seen in state-level declines.

• Act 651-Inspired Co-Prescription Mandates (Federal Support via CDC Guidelines)
  

  Federal CDC guidelines reinforce state laws like Arkansas's Act 651 of 2021, requiring naloxone co-prescription with high-dose opioids to prevent overdoses among patients and communities. It targets prescribers, pharmacies, and patients at risk of misuse. This high-impact action drove a 365% increase in Arkansas naloxone fills from 2021 to 2022, contributing to a 24% overdose death drop in 2024. Nationally, it supports declining prescription rates and overdose reversals.

• Opioid Prescription Rate Reduction Initiatives (CDC Monitoring 2019-2023)
  

  The CDC tracks and promotes reduced opioid prescribing, with national rates dropping as states like Arkansas fell from 81 to 71 prescriptions per 100 people by 2023. It targets healthcare providers through education and data-driven policies to curb supply-driven addiction. This contributes by limiting new dependencies, aligning with Arkansas's twice-national average but improving trend, aiding overall death reductions.

• FAIR Health Opioid Tracker and Diagnosis Surge Response (2021-2024)
  

  FAIR Health's national Opioid Tracker monitors use disorder diagnoses, revealing a 39.8% national rise to 539 per 100,000 by 2024, informing federal funding allocations. It targets commercially insured populations and policymakers for targeted interventions. By highlighting hotspots like Arkansas (1,218 per 100,000), it drives resource deployment, supporting treatment access and cost management at $551,000 per case.

• Synthetic Opioid Disruption Efforts (Ongoing CDC Surveillance)
  

  CDC surveillance addresses synthetic opioids like fentanyl, involved in 69% of 2023 U.S. overdoses and 85.4% of Arkansas's 2023 opioid deaths. It targets illicit supply chains via data sharing with law enforcement and public health. This contributes to declines like Arkansas's 24% drop in 2024, the lowest since 2019, by enabling rapid response to trends.

Arkansas Case - The Numbers Speak for Themselves

Arkansas has seen rising opioid addiction post-pandemic, with opioid use disorder diagnoses at 1,218 per 100,000 commercially insured in 2024—fourth-highest nationally and over twice the U.S. average—despite a 24% drop in total overdose deaths to 391 in 2024 from 516 in 2023. Opioids factored in 60.9% of 314 overdose deaths in 2023, with fentanyl in 85.4%; marijuana-related overdoses are minimal, but general drug deaths peaked at 637 in 2021 before declining. Local authorities respond via programs like ARORP, which trained 10,298 in naloxone use, referred 883 to treatment, and handled 63 fatal/206 non-fatal overdoses.

Mortality: According to the data, more than 300 people die each year in Arkansas due to overdose, with opioids predominant; 314 opioid overdoses occurred in 2023, down from 516 total in 2023.

State programs:

• Arkansas Overdose Response Program (ARORP)
  

  ARORP aims to reduce overdoses through training, response, and treatment referral. It works by training 10,298 people in naloxone use, opening 542 cases, referring 883 to treatment, and making 385 arrests while responding to 63 fatal and 206 non-fatal overdoses. Its impact stabilizes trends, serving mostly 18-65-year-olds and showing positive key outcomes.

• Act 651 Naloxone Co-Prescription Law (2021)
  

  This law requires naloxone with high-dose opioid prescriptions to prevent overdoses. It operates via mandated pharmacy dispensing, boosting fills 365% from 5,595 in FY2021 to 26,042 in FY2022. It contributes to Arkansas's 24% overdose death decline in 2024, lowest since 2019.

• One Pill Can Kill Awareness Campaign
  

  Led by Attorney General Tim Griffin using settlement funds, it educates college campuses on fentanyl risks. It delivers targeted messaging to youth amid high prescription misuse history. Its scope amplifies prevention, supporting broader declines like 45%+ reductions noted nationally for Arkansas.

Approaches in Neighboring Regions

• Missouri
  • Missouri implements expanded naloxone distribution programs similar to federal models, training community members to reverse overdoses quickly.
  • This targets high-risk areas with fentanyl influx, contributing to regional declines by increasing survival rates from non-fatal events.
  • State data shows prescription reductions aiding supply control, mirroring Arkansas trends.
  • Integration with treatment referrals enhances long-term recovery, stabilizing overdose metrics.
• Tennessee
  • Tennessee leads with high opioid diagnosis rates (1,447 per 100,000) but counters via settlement-funded treatment centers.
  • Strategies focus on comprehensive care for commercially insured, reducing post-diagnosis costs through early intervention.
  • Public awareness on synthetics like fentanyl drives behavioral change among 31-50 age groups.
  • This high-impact approach supports workforce productivity by addressing economic burdens.
• Texas
  • Texas emphasizes prescriber education, lowering opioid scripts akin to Arkansas's drop to 71 per 100.
  • Law enforcement partnerships disrupt synthetic supplies, targeting fentanyl in 85%+ of deaths.
  • Community naloxone programs boost reversals, preventing fatalities like Arkansas's daily rate.
  • Youth-focused campaigns build on historical misuse data for prevention.
• Oklahoma
  • Oklahoma uses multi-agency overdose response teams for rapid intervention and arrests.
  • This mirrors ARORP, referring cases to treatment while handling non-fatal events effectively.
  • Settlement funds support research and awareness, enhancing data-driven policies.
  • Declines in deaths demonstrate efficacy in rural, high-risk zones.

Is It Possible to Stop the Crisis? Looking to the Future

Potentially effective approaches:

• Investment in treatment: Expands access like ARORP's 883 referrals, addressing 1,218 diagnoses per 100,000 in Arkansas by providing evidence-based care, reducing relapse and costs at $551,000 per case.
• Early intervention: Naloxone co-prescription via Act 651 boosted fills 365%, preventing deaths and enabling treatment entry, as seen in 24% decline.
• Interagency cooperation: Combines health (ADH data), enforcement (385 arrests), and education, stabilizing trends per ARORP outcomes.
• Educational campaigns: "One pill can kill" targets campuses, leveraging settlements to curb youth misuse historically worst in Arkansas.
• Decriminalization with support: Focuses diversion to treatment over arrests alone, improving referral rates and positive indicators.

Likely ineffective approaches:

• Unaccompanied isolation: COVID-era isolation spiked overdoses by exacerbating mental health without support, worsening 2020-2021 peaks.
• Repressive measures alone: Arrests (385 via ARORP) stabilize but do not reduce root causes without treatment linkage, as misuse rates remain high.
• Lack of aftercare: High diagnosis surges (39.8% nationally) persist without follow-up, leading to costly recurrences at $551,000 per case.

Conclusions and Recommendations

Public health is a shared responsibility demanding urgent action against the drug crisis. Each state charts its path, but success hinges on reliable data like CDC provisional figures, open dialogue via campaigns, and long-term support for addicts through programs like ARORP and naloxone access. Arkansas's 24% decline proves targeted strategies work; scaling them nationally offers hope.